NCT06472570Recruiting
Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
Source: ClinicalTrials.gov · Last updated 25 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 21 May 2024
- Start date
- 26 Oct 2019
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
- Diseases
- Head and neck cancer
- NCT number
- NCT06472570
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 26 Oct 2019 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myocardial infarction occurred up to 6 months before.
Other illness
- Decompensated diabetes mellitus.
- Mental disorder preclusive of making a conscious agreement
Other
- Do not meet the inclusion criteria.
- Pregnancy.
Who the study is looking for
- Patients with squamous cell carcinoma (SCC) or adenoid cystic carcinoma (ACC) of the H\&N region qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy.
- Patients with other malignant tumours of the H\&N region (sarcomas, neuroendocrine carcinomas, differentiated carcinomas, undifferentiated carcinomas, or basaloid carcinomas) qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy.
- Patients with nonmalignant tumours of the H\&N region (tumour mixtus or paraganglioma) demanding definitive or adjuvant radiotherapy.
- Age: 18-80 years. Biomedicines 2022, 10, 1484 5 of 12
- Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
- Conscious agreement to participate in the clinical trial.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Coordinator of this site? Confirm its status | Gliwice | Poland | Recruiting |
Related publications
- High-dose stereotactic radiotherapy boost in the radical treatment of head and neck tumors.Radiat Oncol · 2026 · PMID 42216211
This page is information, not medical advice. Discuss any trial with your doctor.